3rd Cir. Affirms Fen-Phen Settlement, Says Due Process Rights Upheld




PHILADELPHIA -- The 3rd Circuit Court of Appeals on Nov. 30 rejected appeals by three groups of plaintiffs affected by the Wyeth diet drug MDL settlement, finding that plaintiffs were adequately represented and that their due process rights were not violated. In re: Diet Drugs Product Liability Litigation. MDL No. 1203. Nos. 03-3401, 03-3402, 03-4465 and 04-3661 (3rd Cir.).

The nationwide settlement for users of Pondimin (fenfluramine hydrochloride) and Redux (dexfenfluramine) was approved in August 2000 by the U.S. District Court for the Eastern District of Pennsylvania. The settlement allows certain class members to opt out and sue Wyeth individually, …






UPCOMING CONFERENCES




HarrisMartin's Webinar Series: Baby Food Litigation

April 08, 2021 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS



HarrisMartin's Webinar Series: The Elmiron MDL - Hear from the Leadership Counsel

March 05, 2021 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS